Do you want to read an article? Please log in or register.
A population-level real-world analysis and single-center validation of melanoma brain metastasis epidemiology following dual-agent immunotherapy
Skin Cancer
Related content
SPECIAL REPORT
Breast Cancer
Results of TRODELVY® real-world data
ASH 2024
Lymphoma
Liso-cel is effective and safe in a broad real-world population of R/R LBCLa patients, including second-line setting and secondary CNS involvement
Skin Cancer
Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study
Eur J Cancer
Mandalà M, Amaral T, Rutkowski P, Sergi MC, Rasch ML, Benannoune N, Serra P, Vitale MG, Giannarelli D, Arance AM, Couselo EM, Neyns B, Dirven I, Tucci M, Guida M, Spagnolo F, Rossi E, Queirolo P, Quaglino P, Depenni R, Placzke J, Giacomo AMD, Del Vecchio M, Indini A, Silva IPD, Menzies AM, Hong A, Lorigan P, Long GV, Robert C, Ascierto PA
doi: 10.1016/j.ejca.2025.115567
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Front Oncol
Justeau G, Chouaid C, Debieuvre D, Audigier-Valette C, Quantin X, Léna H, Bosquet L, Girard N, Schoemaker MJ, Mella M, Pinto Correia B, Rault C, Daumont MJ, Penrod JR, Lee A, Pérol M
doi: 10.3389/fonc.2025.1526931
Skin Cancer
Long-term follow-up of real-world adjuvant anti-PD1 checkpoint inhibition and targeted therapy in stage III melanoma patients
J Clin Oncol
Lodde GC, Hassel JC, von Wasielewski I, Meier F, Mohr P, Kähler K, Hauschild A, Glutsch V, Stege H, Berking C, Hüning S, Huynh J, Gutzmer R, Reinhardt L, Schilling B, Loquai C, Erdmann M, Stang A, Kowall B, Galetzka W, Roesch A, Tilkorn D, Ugurel S, Zimmer L, Schadendorf D, Forschner A, Livingstone E
doi: 10.1200/JCO-24-02776
Lymphoma
Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers
Haematologica
Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, Dong N, Qualls D, Amoozgar B, Kahl B, Baird J, Challa P, Huntington SF, Santos J, Bair S, Narkhede M, Li S, Frosch Z, Ho C, Smith SD, Winter A, Landsburg D, Furqan F, Hamadani M, Baird K, Romancik J, Alharthy H, Law J, Bojanini L, Advani R, Hu B, Johnson PC, Grover NS, Merril M, Crombie JL, Shafagati N, Sterling C, Nastoupil LJ, Epperla N, Ayers EC
doi: 10.3324/haematol.2024.285977
Lymphoma
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow up
Haematologica
Portuguese AJ, Huang JJ, Jeon Y, Taheri M, Albittar A, Liang EC, Hirayama AV, Kimble EL, Iovino L, Poh C, Gopal AK, Shadman M, Till BG, Milano F, Chapuis AG, Otegbeye F, Cassaday RD, Basom RS, Wu QV, Maloney DG, Gauthier J
doi: 10.3324/haematol.2024.287010
CHICAGO 2025
Genitourinary Cancer
PRECISION: Real-world outcomes following guideline-recommended therapies after 177Lu-PSMA-617 in mCRPC
ASH 2024
Lymphoma